PHENTERMINE HYDROCHLORIDE- phentermine hydrochloride tablet, orally disintegrating Zydus Pharmaceuticals (USA) Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PHENTERAMINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS safely and effectively. See full prescribing information for PHENTERAMINE HYDROCHLORIDE ORALLY DISINTEGRATING TABLETS

PHENTERMINE HYDROCHLORIDE orally disintegrating tablets, for oral use C IV Initial U.S. Approval: 1959

INDICATIONS AND USAGE Phentermine hydrochloride orally disintegrating tablets are sympathomimetic amine anorectic indicated as a short-term adjunct (a few weeks) in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m², or greater than or equal to 27 kg/m² in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia). (1)

The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use. (1)

----- DOSAGE AND ADMINISTRATION -----

- Dosage should be individualized to obtain an adequate response with the lowest effective dose. (2)
- Late evening administration should be avoided (risk of insomnia). (2)
- Phentermine hydrochloride orally disintegrating tablets can be taken with or without food (12.3)

----- DOSAGE FORMS AND STRENGTHS

- Orally disintegrating tablets containing 15 mg, 30 mg, or 37.5 mg phentermine hydrochloride. (3)
- ----- CONTRAINDICATIONS ------
- History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension) (4)
- During or within 14 days following the administration of monoamine oxidase inhibitors (4)
- Hyperthyroidism (4)
- Glaucoma (4)
- Agitated states (4)
- History of drug abuse (4)
- Pregnancy (4, 8.1)
- Nursing (4, 8.3)
- Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines (4)

----- WARNINGS AND PRECAUTIONS -----

- Coadministration with other drugs for weight loss is not recommended (safety and efficacy of combination not established). (5.1)
- Rare cases of primary pulmonary hypertension have been reported. Phentermine hydrochloride should be discontinued in case of new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema. (5.2)
- Rare cases of serious regurgitant cardiac valvular disease have been reported. (5.3)
- Tolerance to the anorectic effect usually develops within a few weeks. If this occurs, phentermine hydrochloride should be discontinued. The recommended dose should not be exceeded. (5.4)
- Phentermine hydrochloride may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. (5.5)
- Risk of abuse and dependence. The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. (5.6)
- Concomitant alcohol use may result in an adverse drug reaction. (5.7)
- Use caution in patients with even mild hypertension (risk of increase in blood pressure). (5.8)
- A reduction in dose of insulin or oral hypoglycemic medication may be required in some patients. (5.9)

------ ADVERSE REACTIONS ------

Adverse events have been reported in the cardiovascular, central nervous, gastrointestinal, allergic, and endocrine systems. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Zydus Pharmaceuticals USA Inc. at 1-877-993-8779 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Monoamine oxidase inhibitors: Risk of hypertensive crisis. (4, 7.1)
- Alcohol: Consider potential interaction (7.2)
- Insulin and oral hypoglycemics: Requirements may be altered. (7.3)
- Adrenergic neuron blocking drugs: Hypotensive effect may be decreased by phentermine hydrochloride (7.4)

------ USE IN SPECIFIC POPULATIONS ------

- Nursing mothers: Discontinue drug or nursing taking into consideration importance of drug to mother. (4, 8.3)
- Pediatric use: Safety and effectiveness not established. (8.4)
- Geriatric use: Due to substantial renal excretion, use with caution. (8.5)
- Use caution when administering phentermine hydrochloride to patients with renal impairment (8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 2/2018

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE
- **2 DOSAGE AND ADMINISTRATION**
- **3 DOSAGE FORMS AND STRENGTHS**

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

- 5.1 Coadministration with Other Drug Products for Weight Loss
- 5.2 Primary Pulmonary Hypertension
- 5.3 Valvular Heart Disease
- 5.4 Development of Tolerance, Discontinuation in Case of Tolerance
- 5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks
- 5.6 Risk of Abuse and Dependence
- 5.7 Usage with Alcohol
- 5.8 Use in Patients with Hypertension
- 5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus

6 ADVERSE REACTIONS

7 DRUG INTERACTIONS

- 7.1 Monoamine Oxidase Inhibitors
- 7.2 Alcohol
- 7.3 Insulin and Oral Hypoglycemic Medications
- 7.4 Adrenergic Neuron Blocking Drugs

8 USE IN SPECIFIC POPULATIONS

- 8.1 Pregnancy
- 8.3 Nursing Mothers
- 8.4 Pediatric Use
- 8.5 Geriatric Use
- 8.6 Renal Impairment

9 DRUG ABUSE AND DEPENDENCE

- 9.1 Controlled Substance
- 9.2 Abuse
- 9.3 Dependence

10 OVERDOSAGE

- 10.1 Acute Overdosage
- 10.2 Chronic Intoxication

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

- 12.1 Mechanism of Action
- 12.2 Pharmacodynamics

12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.3 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 16.2 How Supplied 16.1 Storage 17 PATIENT COUNSELING INFORMATION * Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Phentermine hydrochloride orally disintegrating tablets are indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index greater than or equal to 30 kg/m², or greater than or equal to 27 kg/m² in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia).

Below is a chart of body mass index (BMI) based on various heights and weights.

BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds 2.2 = kg; inches x 0.0254 = meters.

		•			·	
Header\$Weight (pounds)	5'0''	5'3''	5'6''	5'9''	6'0''	6'3''
140	27	25	23	21	19	18
150	29	27	24	22	20	19
160	31	28	26	24	22	20
170	33	30	28	25	23	21
180	35	32	29	27	25	23
190	37	34	31	28	26	24
200	39	36	32	30	27	25
210	41	37	34	31	29	26
220	43	39	36	33	30	28
230	45	41	37	34	31	29
240	47	43	39	36	33	30
250	49	44	40	37	34	31

BODY MASS INDEX (BMI), kg/m² Height(feet, inches)

The limited usefulness of agents of this class, including phentermine hydrochloride, [see *Clinical Pharmacology (12.1, 12.2)*] should be measured against possible risk factors inherent in their use such as those described below.

2 DOSAGE AND ADMINISTRATION

Exogenous Obesity

Dosage should be individualized to obtain an adequate response with the lowest effective dose.

The usual adult dose is one tablet as prescribed by the physician, administered in the morning, with or

without food. Phentermine hydrochloride orally disintegrating tablets are not recommended for use in pediatric patients less than or equal to 16 years of age.

Late evening medication should be avoided because of the possibility of resulting insomnia.

With dry hands, gently remove the phentermine hydrochloride orally disintegrating tablet from the bottle. Immediately place the phentermine hydrochloride orally disintegrating tablet on top of the tongue where it will dissolve, then swallow with or without water.

3 DOSAGE FORMS AND STRENGTHS

Phentermine hydrochloride orally disintegrating tablets (ODT) containing 15 mg, 30 mg, or 37.5 mg phentermine hydrochloride (equivalent to 12 mg, 24 mg, or 30 mg phentermine base, respectively). The tablets are not scored.

- The 15 mg orally disintegrating tablet (ODT) is a white to off-white, round, beveled, biconvex, uncoated tablets, debossed with '703' on one side and plain on other side.
- The 30 mg orally disintegrating tablet (ODT) is a white to off-white, oval, beveled, biconvex, uncoated tablets, debossed with '704' on one side and plain on other side.
- The 37.5 mg orally disintegrating tablet (ODT) is a white to off-white, round, beveled, biconvex, uncoated tablets, debossed with '670' on one side and plain on other side.

4 CONTRAINDICATIONS

- History of cardiovascular disease (e.g., coronary artery disease, stroke, arrhythmias, congestive heart failure, uncontrolled hypertension)
- During or within 14 days following the administration of monoamine oxidase inhibitors
- Hyperthyroidism
- Glaucoma
- Agitated states
- History of drug abuse
- Pregnancy [see Use in Specific Populations (8.1)]
- Nursing [see Use in Specific Populations (8.3)]
- Known hypersensitivity, or idiosyncrasy to the sympathomimetic amines

5 WARNINGS AND PRECAUTIONS

5.1 Coadministration with Other Drug Products for Weight Loss

Phentermine hydrochloride orally disintegrating tablets are indicated only as short-term (a few weeks) monotherapy for the management of exogenous obesity. The safety and efficacy of combination therapy with phentermine hydrochloride orally disintegrating tablets and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. Therefore, coadministration of phentermine hydrochloride orally disintegrating tablets and these drug products is not recommended.

5.2 Primary Pulmonary Hypertension

Primary Pulmonary Hypertension (PPH)

A rare, frequently fatal disease of the lungs-has been reported to occur in patients receiving a combination of phentermine with fenfluramine or dexfenfluramine. The possibility of an association between PPH and the use of phentermine hydrochloride alone cannot be ruled out; there have been rare cases of PPH in patients who reportedly have taken phentermine alone. The initial symptom of PPH is usually dyspnea. Other initial symptoms may include angina pectoris, syncope or lower extremity edema. Patients should be advised to report immediately any deterioration in

exercise tolerance. Treatment should be discontinued in patients who develop new, unexplained symptoms of dyspnea, angina pectoris, syncope or lower extremity edema, and patients should be evaluated for the possible presence of pulmonary hypertension.

5.3 Valvular Heart Disease

Serious regurgitant cardiac valvular disease, primarily affecting the mitral, aortic and/or tricuspid valves, has been reported in otherwise healthy persons who had taken a combination of phentermine with fenfluramine or dexfenfluramine for weight loss. The possible role of phentermine in the etiology of these valvulopathies has not been established and their course in individuals after the drugs are stopped is not known. The possibility of an association between valvular heart disease and the use of phentermine hydrochloride alone cannot be ruled out; there have been rare cases of valvular heart disease in patients who reportedly have taken phentermine alone.

5.4 Development of Tolerance, Discontinuation in Case of Tolerance

When tolerance to the anorectant effect develops, the recommended dose should not be exceeded in an attempt to increase the effect; rather, the drug should be discontinued.

5.5 Effect on the Ability to Engage in Potentially Hazardous Tasks

Phentermine hydrochloride may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; the patient should therefore be cautioned accordingly.

5.6 Risk of Abuse and Dependence

Phentermine hydrochloride is related chemically and pharmacologically to amphetamine (d- and d*l*-amphetamine) and to other related stimulant drugs that have been extensively abused. The possibility of abuse of phentermine hydrochloride should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program. See *Drug Abuse and Dependence (9)* and *Overdosage (10)*.

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

5.7 Usage with Alcohol

Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug reaction.

5.8 Use in Patients with Hypertension

Use caution in prescribing phentermine hydrochloride for patients with even mild hypertension (risk of increase in blood pressure).

5.9 Use in Patients on Insulin or Oral Hypoglycemic Medications for Diabetes Mellitus

A reduction in insulin or oral hypoglycemic medications in patients with diabetes mellitus may be required.

6 ADVERSE REACTIONS

The following adverse reactions are described, or described in greater detail, in other sections:

- Primary pulmonary hypertension [see *Warnings and Precautions* (5.2)]
- Valvular heart disease [see Warnings and Precautions (5.3)]
- Effect on the ability to engage in potentially hazardous tasks [see Warnings and Precautions (5.5)]
- Withdrawal effects following prolonged high dosage administration [see Drug Abuse and Dependence (9.3)]

The following adverse reactions to phentermine have been identified:

Cardio vas cular

Primary pulmonary hypertension and/or regurgitant cardiac valvular disease, palpitation, tachycardia, elevation of blood pressure, ischemic events.

Central Nervous System

Overstimulation, restlessness, dizziness, insomnia, euphoria, dysphoria, tremor, headache, psychosis.

Gas trointes tinal

Dryness of the mouth, unpleasant taste, diarrhea, constipation, other gastrointestinal disturbances.

Allergic

Urticaria.

Endocrine

Impotence, changes in libido.

7 DRUG INTERACTIONS

7.1 Monoamine Oxidase Inhibitors

Use of phentermine hydrochloride is contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors because of the risk of hypertensive crisis.

7.2 Alcohol

Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug reaction.

7.3 Insulin and Oral Hypoglycemic Medications

Requirements may be altered [see Warnings and Precautions (5.9)].

7.4 Adrenergic Neuron Blocking Drugs

Phentermine hydrochloride may decrease the hypotensive effect of adrenergic neuron blocking drugs.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category X

Phentermine hydrochloride is contraindicated during pregnancy because weight loss offers no potential benefit to a pregnant woman and may result in fetal harm. A minimum weight gain, and no weight loss, is currently recommended for all pregnant women, including those who are already overweight or obese, due to obligatory weight gain that occurs in maternal tissues during pregnancy. Phentermine has pharmacologic activity similar to amphetamine (d- and *dl*-amphetamine) [see *Clinical Pharmacology (12.1)*]. Animal reproduction studies have not been conducted with phentermine. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.

8.3 Nursing Mothers

It is not known if phentermine hydrochloride is excreted in humanmilk; however, other amphetamines are present in humanmilk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

8.4 Pediatric Use

Safety and effectiveness in pediatric patients have not been established. Because pediatric obesity is a chronic condition requiring long-term treatment, the use of this product, approved for short-term therapy, is not recommended.

8.5 Geriatric Use

In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

8.6 Renal Impairment

Phentermine hydrochloride was not studied in patients with renal impairment. Based on the reported excretion of phentermine in urine, exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine hydrochloride to patients with renal impairment [see *Clinical Pharmacology (12.3)*].

9 DRUG ABUSE AND DEPENDENCE

9.1 Controlled Substance

Phentermine is a Schedule IV controlled substance.

9.2 Abuse

Phentermine is related chemically and pharmacologically to the amphetamines. Amphetamines and other stimulant drugs have been extensively abused and the possibility of abuse of phentermine should be kept in mind when evaluating the desirability of including a drug as part of a weight reduction program.

9.3 Dependence

Abuse of amphetamines and related drugs may be associated with intense psychological dependence and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times that recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.

10 OVERDOSAGE

The least amount feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage.

10.1 Acute Overdosage

Manifestations of acute overdosage include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include tachycardia, arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea and abdominal cramps. Overdosage of pharmacologically similar compounds has resulted in fatal poisoning usually terminates in convulsions and coma.

Management of acute phentermine hydrochloride intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Experience with hemodialysis or peritoneal dialysis is


inadequate to permit recommendations in this regard. Intravenous phentolamine (Regitine[®], CIBA) has been suggested on pharmacologic grounds for possible acute, severe hypertension, if this complicates overdosage.

10.2 Chronic Intoxication

Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity and personality changes. The most severe manifestation of chronic intoxications is psychosis, often clinically indistinguishable from schizophrenia [see *Drug Abuse and Dependence (9.3)*].

11 DESCRIPTION

Phentermine hydrochloride tablet is an orally disintegrating tablet (ODT) of phentermine hydrochloride. Phentermine hydrochloride is a sympathomimetic amine anorectic. Its chemical name is α , α ,-dimethylphenethylamine hydrochloride. The structural formula is as follows:



C 10H 15 N. HCl M.W. 185.69

Phentermine hydrochloride, USP is a white, odorless, hygroscopic, crystalline powder which is soluble in water and lower alcohols, slightly soluble in chloroform and insoluble in ether.

Phentermine hydrochloride is available as an orally disintegrating tablet (ODT) containing 15 mg, 30 mg, or 37.5 mg of phentermine hydrochloride (equivalent to 12 mg, 24 mg, or 30 mg of phentermine base). In addition each tablet contains following inactive ingredients: colloidal silicon dioxide, crospovidone, magnesium stearate, mannitol, microcrystalline cellulose, peppermint flavor, povidone, silicon dioxide, sodium lauryl sulfate, sodium stearyl fumarate, sucralose and talc.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Phentermine hydrochloride is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and dll-amphetamine). Drugs of this class used in obesity are commonly known as "anorectics" or "anorexigenics." It has not been established that the primary action of such drugs in treating obesity is one of appetite suppression since other central nervous system actions, or metabolic effects, may also be involved.

12.2 Pharmacodynamics

Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with all drugs of this class in which these phenomena have been looked for.

12.3 Pharmacokinetics

In terms of rate and extent of exposure, phentermine hydrochloride orally disintegrating tablets are equivalent to phentermine capsules and tablets administered under fasting conditions.

Following the administration of the oral disintegrating tablet (ODT), phentermine reaches peak

concentrations (C_{max}) after 3 to 4.4 hours. Swallowing the ODT after disintegration with or without water did not affect the extent (AUC) of phentermine exposure.

Administration of the orally disintegrating tablet (ODT) after a high fat/high calorie breakfast decreased the C_{max} of phentermine by approximately 5% and the AUC by approximately 12%. Despite the decrease in C_{max} and AUC, phentermine hydrochloride orally disintegrating tablet can be administered with or without food.

Swallowing the orally disintegrating tablet (ODT) without prior disintegration decreased the C_{max} of phentermine by approximately 7% and the AUC by approximately 8% compared to swallowing the ODT after disintegration.

Drug Interactions

In a single-dose study comparing the exposures after oral administration of a combination capsule of 15 mg phentermine and 92 mg topiramate to the exposures after oral administration of a 15 mg phentermine capsule or a 92 mg topiramate capsule, there is no significant topiramate exposure change in the presence of phentermine. However in the presence of topiramate, phentermine C_{max} and AUC increase 13% and 42%, respectively.

Specific Populations

Renal Impairment

Phentermine hydrochloride was not studied in patients with renal impairment. The literature reported cumulative urinary excretion of phentermine under uncontrolled urinary pH conditions is 62% to 85%. Exposure increases can be expected in patients with renal impairment. Use caution when administering phentermine hydrochloride to patients with renal impairment.

13 NONCLINICAL TOXICOLOGY

13.3 Carcinogenesis, Mutagenesis, Impairment of Fertility

Studies have not been performed with phentermine hydrochloride to determine the potential for carcinogenesis, mutagenesis or impairment of fertility.

14 CLINICAL STUDIES

No clinical studies have been conducted with phentermine hydrochloride.

In relatively short-term clinical trials, adult obese subjects instructed in dietary management and treated with "anorectic" drugs lost more weight on the average than those treated with placebo and diet.

The magnitude of increased weight loss of drug-treated patients over placebo-treated patients is only a fraction of a pound a week. The rate of weight loss is greatest in the first weeks of therapy for both drug and placebo subjects and tends to decrease in succeeding weeks. The possible origins of the increased weight loss due to the various drug effects are not established. The amount of weight loss associated with the use of an "anorectic" drug varies from trial to trial, and the increased weight loss appears to be related in part to variables other than the drugs prescribed, such as the physician-investigator, the population treated and the diet prescribed. Studies do not permit conclusions as to the relative importance of the drug and non-drug factors on weight loss.

The natural history of obesity is measured over several years, whereas the studies cited are restricted to a few weeks' duration; thus, the total impact of drug-induced weight loss over that of diet alone must be considered clinically limited.

16 HOW SUPPLIED/STORAGE AND HANDLING

16.2 How Supplied

Phentermine hydrochloride orally disintegrating tablets, 15 mg are white to off-white, round, beveled,

biconvex, uncoated tablets, debossed with '703' on one side and plain on other side and are supplied as follows:

NDC 68382-703-06 in bottle of 30 tablets

NDC 68382-703-16 in bottle of 90 tablets

NDC 68382-703-01 in bottle of 100 tablets

NDC 68382-703-05 in bottle of 500 tablets

NDC 68382-703-10 in bottle of 1000 tablets

NDC 68382-703-77 in unit-dose blister cartons of 100 (10 x 10) unit dose tablets

Phentermine hydrochloride orally disintegrating tablets, 30 mg are white to off-white, oval, beveled, biconvex, uncoated tablets, debossed with '704' on one side and plain on other side and are supplied as follows:

NDC 68382-704-06 in bottle of 30 tablets

NDC 68382-704-16 in bottle of 90 tablets

NDC 68382-704-01 in bottle of 100 tablets

NDC 68382-704-05 in bottle of 500 tablets

NDC 68382-704-10 in bottle of 1000 tablets

NDC 68382-704-77 in unit-dose blister cartons of 100 (10 x 10) unit dose tablets

Phentermine hydrochloride orally disintegrating tablets, 37.5 mg are white to off- white, round, beveled, biconvex, uncoated tablets, debossed with '670' on one side and plain on other side and are supplied as follows:

NDC 68382-670-06 in bottle of 30 tablets

NDC 68382-670-16 in bottle of 90 tablets

NDC 68382-670-01 in bottle of 100 tablets

NDC 68382-670-05 in bottle of 500 tablets

NDC 68382-670-10 in bottle of 1000 tablets

NDC 68382-670-77 in unit-dose blister cartons of 100 (10 x 10) unit dose tablets

16.1 Storage

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Dispense in a tightly closed container with a child-resistant closure (as required).

Protect from moisture.

Keep out of the reach of children.

17 PATIENT COUNSELING INFORMATION

Patients must be informed that phentermine hydrochloride is a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity, and that coadministration of phentermine with other drugs for weight loss is not recommended [see *Indications and Usage (1)* and *Warnings and Precautions (5)*].

Patients must be instructed on how much phentermine hydrochloride orally disintegrating tablets to take, and when and how to take it [see *Dosage and Administration (2)*].

Advise pregnant women and nursing mothers not to use phentermine hydrochloride orally disintegrating tablet [see *Use in Specific Populations (8.3)*].

Patients must be informed about the risks of use of phentermine (including the risks discussed in Warnings and Precautions), about the symptoms of potential adverse reactions and when to contact a physician and/or take other action. The risks include, but are not limited to:

- Development of primary pulmonary hypertension [see *Warnings and Precautions (5.2)*]
- Development of serious valvular heart disease [see *Warnings and Precautions* (5.3)]
- Effects on the ability to engage in potentially hazardous tasks [see *Warnings and Precautions* (5.5)]
- The risk of an increase in blood pressure [see Warnings and Precautions (5.8) and Adverse Reactions (6)]
 The risk of interview [see Control of the second seco
- The risk of interactions [see *Contraindications* (4), *Warnings and Precautions* (5) *and Drug Interactions* (7)]

See also, for example, Adverse Reactions (6) and Use in Specific Populations (8).

The patients must also be informed about

- the potential for developing tolerance and actions if they suspect development of tolerance [see *Warnings and Precautions (5.4)*] and
- the risk of dependence and the potential consequences of abuse [see *Warnings and Precautions* (5.6), *Drug Abuse and Dependence* (9), and *Overdosage* (10)].

Tell patients to keep phentermine hydrochloride orally disintegrating tablets in a safe place to prevent theft, accidental overdose, misuse or abuse. Selling or giving away phentermine hydrochloride orally disintegrating tablets may harm others and is against the law.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088, or by visiting www.fda.gov/medwatch.

*are the registered trademark of their respective owners.

Manufactured By:

Cadila Healthcare Limited,

Survey no. 417, 419 & 420,

Sarkhej Bavla National Highway No. 8 A,

Village - Moraiya, Tal - Sanand,

Dist. - Ahmedabad, India

Distributed by:

Zydus Pharmaceuticals USA Inc.

Pennington, NJ 08534

Rev.:02/14

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 68382-703-01 in bottle of 100 Tablets Phentermine Hydrochloride Orally Disintegrating Tablets, 15 mg Rx only 100 Tablets ZYDUS



NDC 68382-704-01 in bottle of 100 Tablets

Phentermine Hydrochloride Orally Disintegrating Tablets, 30 mg

Rx only

100 Tablets

ZYDUS



NDC 68382-670-01 in bottle of 100 Tablets Phentermine Hydrochloride Orally Disintegrating Tablets, 37.5 mg Rx only

100 Tablets



PHENTERMINE HYDROCHLORIDE phentermine hydrochloride tablet, orally disintegrating **Product Information** HUMAN PRESCRIPTION DRUG NDC:68382-703 **Product Type** Item Code (Source) **Route of Administration** ORAL CIV **DEA Schedule Active Ingredient/Active Moiety Basis of Strength Strength Ingredient** Name PHENTERMINE HYDRO CHLO RIDE (UNII: 0K2I5050TV) (PHENTERMINE - UNII:C045TQL4WP) PHENTERMINE 15 mg **Inactive Ingredients Ingredient** Name Strength SILICON DIO XIDE (UNII: ETJ7Z6 XBU4) CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960 MK) MAGNESIUM STEARATE (UNII: 70097M6I30) MANNITOL (UNII: 30WL53L36A) CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U) PEPPERMINT (UNII: V95R5KMY2B) POVIDONE K30 (UNII: U725QWY32X) SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI) SUCRALOSE (UNII: 96K6UQ3ZD4) TALC (UNII: 7SEV7J4R1U)

Product Characteristics						
Color	WHITE (white to off-white)	Score	no score			
Shape	ROUND (round)	Size	8 m m			
Flavor	PEPPERMINT (peppermint flavour)	Imprint Code	703			
Contains						

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68382-703- 06	30 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
2	NDC:68382-703-16	90 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
3	NDC:68382-703-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
4	NDC:68382-703-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
5	NDC:68382-703-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
6	NDC:68382-703-77	10 in 1 CARTON	02/08/2018	
6	NDC:68382-703-30	10 in 1 BLISTER PACK; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA204663	02/08/2018	

PHENTERMINE HYDROCHLORIDE

phentermine hydrochloride tablet, orally disintegrating

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68382-704
Route of Administration	ORAL	DEA Schedule	CIV

Active Ingredient/Active Moiety			
Ingredient Name	Basis of S	trength	Strengtl
PHENTERMINE HYDRO CHLORIDE (UNI: 0K2I505OTV) (PHENTERMINE - UNII:C045TQL4WP)	PHENTERMI	NE	30 mg
Inactive Ingredients			
Ingredient Name		Str	ength
SILICON DIO XIDE (UNII: ETJ7Z6 XBU4)			
CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)			
MAGNESIUM STEARATE (UNII: 70097M6I30)			
MANNITOL (UNII: 30WL53L36A)			
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)			
PEPPERMINT (UNII: V95R5KMY2B)			
POVIDONE K30 (UNII: U725QWY32X)			

SODIUM LAURYL SULFATE (UNII: 368GB5141J) SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)

PALOSE (UNII)	06K61(03ZD4)		
	• ,		
duct Charac	teristics		
)r	WHITE (white to off-white)	Score	no score
pe (OVAL (oval)	Size	14mm
or	PEPPERMINT (peppermint flavour)	Imprint Code	704
tains			
kaging			
Item Code	Package Description	Marketing Start Date	Marketing End Date
DC:68382-704-	30 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
DC:68382-704-16	90 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
DC:68382-704-0	1 100 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
DC:68382-704-0	5 500 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
DC:68382-704-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018	
DC:68382-704-7	7 10 in 1 CARTON	02/08/2018	
DC:68382-704-30	10 in 1 BLISTER PACK; Type 0: Not a Combination Product		
ırketing In	formation		
r keting In		Marketing Start Date	Marketing End Date
	C (UNII: 7SEV7J4 duct Charact pr	pe OVAL (oval) or PEPPERMINT (peppermint flavour) tains PEPPERMINT (peppermint flavour) kaging Package Description DC:68382-704- 30 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-01 100 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-05 500 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-05 500 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-05 500 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-05 1000 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-10 1000 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-10 100 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-10 100 in 1 BOTTLE; Type 0: Not a Combination Product DC:68382-704-10 10 in 1 CARTON DC:68382-704-30 10 in 1 BLISTER PACK; Type 0: Not a Combination	C (UNII: 7SEV7J4RIU) duct Characteristics yr WHITE (white to off-white) pe OVAL (oval) Size Imprint Code PEPPERMINT (peppermint flavour) tains become set of the s

PHENTERMINE HYDROCHLORIDE

phentermine hydrochloride tablet, orally disintegrating

Product Information						
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:68382-670			
Route of Administration	ORAL	DEA Schedule	CIV			

Active Ingredient/Active Moiety						
Ingredient Name	Basis of Stren	gth Strength				
PHENTERMINE HYDRO CHLORIDE (UNII: 0K2I5050TV) (PHENTERMINE - UNII:C045TQL4WP) PHENTERMINE		37.5 mg				
Inactive Ingredients						
Ingredient Name		Strength				
SILICON DIO XIDE (UNII: ETJ7Z6 XBU4)						
CROSPOVIDONE (15 MPA.S AT 5%) (UNII: 68401960MK)						
MAGNESIUM STEARATE (UNII: 70097M6I30)						
MANNITOL (UNII: 30WL53L36A)						
CELLULOSE, MICROCRYSTALLINE (UNII: OP1R32D61U)						

PEPPERMINT (UNII: V95R5KMY2B)	
POVIDONE K30 (UNII: U725QWY32X)	
SODIUM LAURYL SULFATE (UNII: 368GB5141J)	
SODIUM STEARYL FUMARATE (UNII: 7CV7WJK4UI)	
SUCRALOSE (UNII: 96K6UQ3ZD4)	
TALC (UNII: 7SEV7J4R1U)	

Product Characteristics							
Color	WHITE (WHITE TO OFF-WHITE)	Score	no score				
Shape	ROUND (ROUND)	Size	11mm				
Flavor	PEPPERMINT (PEPPERMINT)	Imprint Code	670				
Contains							

Packaging

-	I ackaging						
#	Item Code	Package Description	Marketing Start Date	Marketing End Date			
1	NDC:68382-670- 06	30 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018				
2	NDC:68382-670-16	90 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018				
3	NDC:68382-670-01	100 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018				
4	NDC:68382-670-05	500 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018				
5	NDC:68382-670-10	1000 in 1 BOTTLE; Type 0: Not a Combination Product	02/08/2018				
6	NDC:68382-670-77	10 in 1 CARTON	02/08/2018				
6	NDUC68382-670-30	10 in 1 BLISTER PACK; Type 0: Not a Combination Product					
N	Marketing Information						
N	Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date			
A	NDA	ANDA204663	02/08/2018				

Labeler - Zydus Pharmaceuticals (USA) Inc. (156861945)

Registrant -	Zydus	Pharmaceuticals	(USA)	Inc.	(156861945)
---------------------	-------	-----------------	-------	------	-------------

Establishment						
Name	Address	ID/FEI	Business Operations			
Cadila Healthcare Limited		9 18 59 6 19 8	ANALYSIS(68382-703, 68382-704, 68382-670), MANUFACTURE(68382-703, 68382-704, 68382-670)			

Revised: 11/2019

Zydus Pharmaceuticals (USA) Inc.